Merck is discontinuing development of MK-7710 (formerly known as CD24Fc), a Phase III Covid-19 therapeutic asset acquired from OncoImmune during November 2020.

Merck will have to wait to see if a Covid-19 therapeutic gained in November through the $425 million acquisition of OncoImmune can receive Emergency Use Authorization (EUA) after the U.S. Food and Drug Administration requested additional data beyond the Phase III study announced during 2020

Merck is stopping development of the company’s two Covid-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.

Merck acquired Maryland-based OncoImmune and the Covid-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.